Search
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigationalGaretosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP). … [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups.
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational_C. botulinum_ is known to produce toxins that can cause botulism in humans. … DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent.
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalFluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.
Categories: Antidepressive Agents Indicated for Depression, P-glycoprotein inhibitorsZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Aminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnAminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia.
Acetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedSulfisoxazole acetyl competes with PABA for the bacterial enzyme, _dihydropteroate synthase_, preventing the incorporation of PABA into dihydrofolic acid, which is the precursor of folic acid. … Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsLB-P8
go.drugbank.com/drugs/DB18535InvestigationalLB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).
Candicidin
go.drugbank.com/drugs/DB01152ApprovedInvestigationalWithdrawnCandicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans).
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsHistrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawnAs the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700] … [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition.
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsVorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates